Abarelix 50 mg/ML Injectable Suspension [Plenaxis]
RxNorm 402101

Concept Hierarchy & Relationship Mapping

RxNorm Concept Unique Identifier (RxCUI) 402101 represents a standardized clinical drug concept used for cross-system interoperability. This concept aggregates multiple Atom IDs (AUIs), which are specific naming variations and synonyms used across pharmaceutical databases to ensure accurate medication mapping for: abarelix 50 mg/ML Injectable Suspension [Plenaxis].

The following semantic concepts and normalized strings are associated with this clinical entity:

SBD
Abarelix 50 mg/ML Injectable Suspension [Plenaxis]
AUI:1660712
View
SY
Plenaxis 50 mg/ML Injectable Suspension
AUI:1660715
View

This clinical crossover tool is designed for healthcare professionals, pharmacists, and data analysts to safely compare substitute products and manage medication interoperability.

SBD

Semantic Branded Drug (SBD):
Abarelix 50 mg/ML Injectable Suspension [Plenaxis]
(Atom ID: 1660712)

Clinical Status & Identity

Prescribable Status
NO (Reference)
Part of the RxNorm Current Prescribable Content subset including all drugs available for prescription in the USA.
Concept Description
abarelix 50 MG/ML Injectable Suspension [Plenaxis]
Official description of the drug concept as defined in the source vocabulary.
Suppress Flag
O
N: Not suppressible | O: Obsolete | Y: Suppressed by editor | E: Unquantified non-prescribable drug.

Interoperability & Coding

Concept ID (RxCUI)
402101
RxNorm Unique Identifier for the standardized concept.
Atom ID (RXAUI)
1660712
Unique identifier for this specific name variation (Atom).
Term Type (TTY)
SBD
Semantic Branded Drug (Ingredient + Strength + Dose Form + Brand Name)
Source Code
402101
The "Most useful" identifier asserted by the original source vocabulary.

Source & Registry Data

Source Name
RxNorm Vocabulary (RXNORM)
The official name and abbreviation for the vocabulary source.
Source Version
20AA_260601F
The specific version of the vocabulary provided by the source.
Update Date
June 01, 2026
The date when this RxNorm data was last updated by the NLM.
License Contact
RxNorm Customer Service, , U.S. National Library of Medicine, 8600 Rockville Pike, , Bethesda, MD, United States, 20894, (888) FIND-NLM, , https://support.nlm.nih.gov/support/create-case/, https://www.nlm.nih.gov/research/umls/rxnorm/
Source licensing contact information.

Technical Attributes & Logic

RXN ACTIVATED
02/17/2006
Date the RxNorm atom was reactivated
RXN OBSOLETED
01/20/2006
Date the RxNorm atom became obsolete
RXN OBSOLETED
02/27/2013
Date the RxNorm atom became obsolete
RXTERM FORM
Susp
The RxTerm dose form name for this drug
SY

Synonym (SY):
Plenaxis 50 mg/ML Injectable Suspension
(Atom ID: 1660715)

Clinical Status & Identity

Prescribable Status
NO (Reference)
Part of the RxNorm Current Prescribable Content subset including all drugs available for prescription in the USA.
Concept Description
Plenaxis 50 MG/ML Injectable Suspension
Official description of the drug concept as defined in the source vocabulary.
Suppress Flag
O
N: Not suppressible | O: Obsolete | Y: Suppressed by editor | E: Unquantified non-prescribable drug.

Interoperability & Coding

Concept ID (RxCUI)
402101
RxNorm Unique Identifier for the standardized concept.
Atom ID (RXAUI)
1660715
Unique identifier for this specific name variation (Atom).
Term Type (TTY)
SY
Synonym (Synonym of another TTY, given for clarity.)
Source Code
402101
The "Most useful" identifier asserted by the original source vocabulary.

Source & Registry Data

Source Name
RxNorm Vocabulary (RXNORM)
The official name and abbreviation for the vocabulary source.
Source Version
20AA_260601F
The specific version of the vocabulary provided by the source.
Update Date
June 01, 2026
The date when this RxNorm data was last updated by the NLM.
License Contact
RxNorm Customer Service, , U.S. National Library of Medicine, 8600 Rockville Pike, , Bethesda, MD, United States, 20894, (888) FIND-NLM, , https://support.nlm.nih.gov/support/create-case/, https://www.nlm.nih.gov/research/umls/rxnorm/
Source licensing contact information.